Cargando…

Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review

Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Zheng, Yao, Zhi-Hua, Yao, Shu-Na, Xia, Qing-Xin, Wang, Hai-Ying, Chu, Jun-Feng, Song, Ming, Zhao, Shuang, Liu, Yan-Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394502/ https://www.ncbi.nlm.nih.gov/pubmed/32801876 http://dx.doi.org/10.2147/CMAR.S254007

Ejemplares similares

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
por: Armand, Philippe, et al.
Publicado: (2019)

Successful Management of Primary Mediastinal Large B-cell Lymphoma during Pregnancy
por: Hashimoto, Yoshinori, et al.
Publicado: (2019)

The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma
por: Tomassetti, Sarah, et al.
Publicado: (2019)

Mediastinal cryptococcosis masquerading as therapy-refractory lymphoma
por: Wong, Matthew, et al.
Publicado: (2010)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
por: Sakaguchi, Hiroyuki, et al.
Publicado: (2021)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
por: Rechner, Laura Ann, et al.
Publicado: (2020)

Mediastinal large-cell lymphoma with sclerosis (MLCLS).
por: Rohatiner, A. Z., et al.
Publicado: (1994)

Primary Mediastinal Large B-cell Lymphoma
por: Dabrowska-Iwanicka, Anna, et al.
Publicado: (2014)

Primary mediastinal large B cell lymphoma
por: Yu, Yating, et al.
Publicado: (2021)

Primary mediastinal large B‐cell lymphoma
por: Villa, Diego, et al.
Publicado: (2020)

A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma
por: Milgrom, Sarah A., et al.
Publicado: (2019)

Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma
por: Smith, Jasmine, et al.
Publicado: (2021)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

PD-L1(+) macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2023)

Radiotherapy of unicentric mediastinal Castleman's disease
por: Li, Yue-Min, et al.
Publicado: (2011)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review
por: Huang, Gang, et al.
Publicado: (2020)

PD-L1 Status in Refractory Lymphomas
por: Vranic, Semir, et al.
Publicado: (2016)

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
por: Macapagal, Sharina C, et al.
Publicado: (2022)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
por: Houot, Roch, et al.
Publicado: (2022)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
por: Bennani, N Nora, et al.
Publicado: (2022)

P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS
por: Steiner, R., et al.
Publicado: (2022)

Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma
por: Griffin, Liezel L., et al.
Publicado: (2018)

Successful Chemo-Radiotherapy for Primary Anaplastic Large Cell Lymphoma of the Lung: A Case Report and Literature Review
por: Zhao, Qian, et al.
Publicado: (2016)

Heart of Lymphoma: Primary Mediastinal Large B-Cell Lymphoma with Endomyocardial Involvement
por: Rogowitz, Elisa, et al.
Publicado: (2013)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma
por: Aoki, T, et al.
Publicado: (2015)

PB2309: OUTCOMES OF 22 PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: SINGLE INSTITUTE EXPERIENCE
por: Tumyan, Gayane, et al.
Publicado: (2023)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
por: Cheng, Lili, et al.
Publicado: (2021)

Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
por: Hanel, Walter, et al.
Publicado: (2023)

Successful treatment of radiotherapy and apatinib in patient with mediastinal mixed non-seminomatous germ cell tumor: A case report
por: Ren, Congcong, et al.
Publicado: (2021)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Primary Mediastinal Large B-Cell Lymphoma during Pregnancy
por: Perez, Cesar A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j12ppj251sf8f2v3tjum7fvjrf